Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X 7 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 15, 2010, Pages 4653-4656

  Beswick, Paul J ^a   Billinton, Andy ^a   Chambers, Laura J ^a   Dean, David K ^a   Fonfria, Elena ^a   Gleave, Robert J ^a   Medhurst, Stephen J ^a   Michel, Anton D ^a   Moses, Andrew P ^a   Patel, Sadhana ^a   Roman, Shilina A ^a   Roomans, Sue ^a   Senger, Stefan ^a   Stevens, Alexander J ^a   Walter, Daryl S ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

P2X 7; Pain; SAR

Indexed keywords

ACETAMIDE DERIVATIVE; CELECOXIB; FREUND ADJUVANT; PURINERGIC P2X7 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; IN VIVO STUDY; NONHUMAN; PAIN; PAIN ASSESSMENT; RAT; STRUCTURE ACTIVITY RELATION;

ACETAMIDES; ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; PAIN; PURINERGIC P2X RECEPTOR ANTAGONISTS; PYRAZOLES; RATS; RECEPTORS, PURINERGIC P2X7; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; RATTUS;

EID: 77955414233     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.05.107     Document Type: Article

References (24)

1. G. Collo, S. Neidhart, E. Kawashima, M. Kosco-Vibois, R.A. North, and G. Buell Neuropharmacology 36 1997 1277
2. F. DiVirgilio, V. Vishwanath, and D. Ferrari M.P. Abbraccio, M. Williams, Handbook of Experimental Pharmacology Vol. 151 2001 Springer 355 373
3. H.P. Buisman, T.H. Steinberg, J. Fischbarg, S.C. Silverstein, S.A. Vogelzang, C. Ince, D.L. Ypey, and P.C. Leijh Proc. Natl. Acad. Sci. U.S.A. 85 1988 7988
4. D. Ferrari, C. Pizzirani, E. Adinolfi, R.M. Lemoli, A. Curti, M. Idzko, E. Panther, and F. Di Virgilio J. Immunol. 176 2006 3877
5. D. Fields, and G. Burnstock Nat. Rev. Neurosci. 7 2006 423
6. I.P. Chessel, J.P. Hatcher, C. Bountra, A.D. Michel, J.P. Hughes, P. Green, J. Egerton, M. Murfin, J. Richardson, W.L. Peck, C.B.A. Grahames, M.A. Casula, Y. Yiangou, R. Birch, P. Anand, and G.N. Buell Pain 114 2005 386
7. P.M. Honore, D. Donnelly-Roberts, M. Namovic, G. Hsieh, C. Zhu, J. Mikusa, G. Hernandez, C. Zhong, D.M. Gauvin, P. Chandran, R. Harris, A.P. Medrano, W. Carroll, K. Marsh, J.P. Sullivan, C.R. Faltynek, and M.F. Jarvis J. Pharmacol. Exp. Ther. 319 2006 1376
8. D.C. Broom, D.J. Matson, E. Bradshaw, M.E. Buck, R. Meade, S. Coombs, M. Matchett, K.K. Ford, W. Yu, J. Yuan, S.H. Sun, R. Ochoa, J.E. Krause, D.J. Wustrow, and D.N. Cortright J. Pharmacol. Exp. Ther. 327 2008 620
9. A. Perez-Medrano, D.L. Donnelly-Roberts, P. Honore, G.C. Hsieh, M.T. Namovic, S. Peddi, Q. Shuai, Y. Wang, C.R. Faltynek, M.F. Jarvis, and W.A. Carroll J. Med. Chem. 52 2009 3366
10. D.W. Nelson, R.J. Gregg, M.E. Kort, A. Perez-Medrano, E.A. Voight, Y. Wang, G. Grayson, M.T. Namovic, D.L. Donnelly-Roberts, W. Niforatos, P. Honore, M.F. Jarvis, C.R. Faltynek, and W.A. Carroll J. Med. Chem. 49 2006 3659
11. McInnes, I.B.; Snell, N.J.; Perrett, J.H.; Parmar, H.; Wang, M.M.; Astbury, C. Arthritis Rheum. [71st Annu Sci Meet Am Coll Rheumatol (Nov 6-11, Boston) 2007], 2007, 56 (9, Suppl.): Abst 2085.
12. ClinicalTrial.gov Identifier: NCT00628095.
13. L.J. Chambers, A.J. Stevens, A.P. Moses, A.D. Michel, B. Slingsby, D.S. Walter, D.J. Davies, D.J. Livermore, E. Fonfria, E.H. Demont, M. Vimal, P.J. Theobald, P.J. Beswick, R.J. Gleave, S.A. Roman, S. Senger, and S. Roomans Bioorg. Med. Chem. Lett. 20 2010 3161
14. WO 2007/141267A1; WO 2007/141269A1; WO 2008/125600A1.
15. max values of 100%. Full details of the assay protocol can be found in patent application WO 2007 141267 A1.
16. S.E. Clarke, and P. Jeffrey Xenobiotica 31 2001 591
17. C. Abad-Zapatero Expert Opin. Drug Discov. 2 2007 469 488
18. P.D. Leeson, and B. Springthorpe Nat. Rev. Drug Disc. 6 2007 881
19. The same concept was independently proposed by researchers at Pfizer and termed lipE T. Ryckmans, M.P. Edwards, V.A. Horne, A. Monica Correia, D.R. Owen, L.R. Thompson, I. Tran, M.F. Tutt, and T. Young Bioorg. Med. Chem. Lett. 15 2009 4406
20. M.J. Iadarola, J. Douglass, O. Civelli, and J.R. Naranjo Brain Res. 455 1988 205
21. C.H. Hay, M.A. Trevethick, A. Wheeldon, J.S. Browers, and J.S. De Belleroche Neuroscience 78 1997 843
22. A.W. Wilson, S.J. Medhurst, C.I. Dixon, N.C. Bontoft, L.A. Winyard, K.T. Brackenborough, J. De Alba, C.J. Clarke, M.J. Gunthorpe, G.A. Hicks, C. Bountra, D.S. McQueen, and I.P. Chessell Eur. J. Pain 10 2006 537 549
23. Calculated log D values were obtained using ACD Labs software v8.0.
24. All experiments were performed in accordance with the United Kingdom Animals (Scientific Procedures) Act, 1986 under Project Licence as well as under the review and approval of the GlaxoSmithKline Procedures Review Panel. GlaxoSmithKline safety regulations were adhered to at all times.